Today s Talk. - A) Biotech Industry in Québec, US & Europe. - B) Valeo Management, L.P. & commercialization of academic research in Québec

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Today s Talk. - A) Biotech Industry in Québec, US & Europe. - B) Valeo Management, L.P. & commercialization of academic research in Québec"

Transcription

1 October 18, 2005 THE COMMERCIALIZATION OF ACADEMIC RESEARCH RESULTS IN THE BIOTECH SECTOR Alain Richard, Ph.D. (MicrobiologyImmunology) o Management, L.P. (Montreal, QC, Canada) Director Commercialization ; Life Sciences

2 Today s Talk A) Biotech Industry in Québec, US & Europe B) o Management, L.P. & commercialization of academic research in Québec C) Case 1: spinoff company: Angiochem, bloodbrain barrier) D) Case 2: transfer through licenses: enteric coating technology E) Concluding remarks & jobs in life science commercialization Gestion o s.e.c.

3 A) Biotech Industry (Québec, US, Europe) 35 % of Canadian Biotech Companies Canada (24 % of the population) Fourth cluster in North America (CAMAONQC); health; agriculture; environment. # 1 in financing in Canada; # 1 in University research spending in Canada (Montréal 20,6 %; Toronto 14,2 %) 110 companies; consolidation nowadays 25 companies listed on a stock exchange (5 are profitable) Revenue increase = annual rate of 61.3 % ( ); expenditure increase on R&D = 28% Sources: Bio Quebec, Investissement Quebec, Statistics Canada 2001 Biotechnology Use and Development Survey Gestion o s.e.c.

4 A) Biotech Industry (Québec, US, Europe) Gestion o s.e.c.

5 B) o Management, L.P. Commercialization of academic research in Québec: o Management, L.P. is one of the four valorization organisms in Québec (one per group of universities) Université du Québec à Montréal (UQAM), École de Technologie Supérieure (ÉTS), Université du Québec à Rimouski (UQAR), Concordia University Financed by Governments (Valorisationrecherche Québec, Canada Economic Development ) & Universities Need for more technology maturation inside universities o 9 employees Gestion o s.e.c.

6 B) o Management, L.P. R&D $ R&D $ R&D $ R&D $ CONCORDIA UNIVERSITY UQAM ÉTS UQAR IP IP IP IP Valorbec L.P. Transfert Plus L.P. Socovar L.P. Rival L.P. Pooled IP Management o L.P. Commercialization Gestion o s.e.c.

7 Innovation Innovation from from Researchers Researchers Disclosure University University o Management General Process EVALUATION EVALUATION (four (four criteria) criteria) Assignment University s University s L.P. L.P. Revenue Market Royalties Sales IP IP Protection Protection Technology Technology Commercial Commercial (positioning) (positioning) Research Research Team Team DEVELOPMENT DEVELOPMENT (Proof (Proof of of concept) concept) 12month 12month Duration Duration $ $ The The private private sector sector will will not not usually usually fund fund such such development development COMMERCIALIZATION COMMERCIALIZATION DEVELOPMENT DEVELOPMENT IP IP MANAGEMENT MANAGEMENT FIND FIND LICENSEES LICENSEES or or SPINOFF SPINOFF VALEO VALEO External Experts Partners Commercial Technical Funding o VRQPrivate Gestion o s.e.c.

8 B) o Management, L.P. Activity (after 4 years) Reçu Éval. Valor. Dériv. Licen. Retour Brevets Brevets soumis émis 31août UQAM Concordia ÉTS UQAR septembre Biotechnology, Health 37 Telecomm. IT 28 Industrial Technologies 3 Technologies in the Arts Licences around the bases 3 rd base 8 2 nd base 14 1 st base 8 At the bat 8 8 Gestion o s.e.c.

9 C) Case 1: Spinoff Company by o (AngioChem AngioChem) Profile : AngioChem is a leadingedge Lavalbased biotechnology company incorporated in 2003 as a spinoff company from the Université du Québec à Montréal. Development of a technology platform allowing the delivery of drugs to the brain without breaking the integrity of the BloodBrain Barrier (BBB). Potential to become a leader in the field of Central Nervous System (CNS) disorders Gestion o s.e.c.

10 C) Case 1: Spinoff Company by o: AngioChem Gestion o s.e.c.

11 C) Case 1: Spinoff Company by o (AngioChem AngioChem) Why a spinoff? A Unmet medical need (98 % of the potential drugs cannot cross the BBB). B No good alternative technology for BBB crossing. C The brain oncology market is over US $10 billions. With sales of up to US $52 billion in 2001 and an annual growth rate of over 10%, the CNS market represents the second largest therapeutic segment of the pharmaceutical market, and one of the fastest growing. D Brain glioma treatment: Orphan drug status possible; due to generally poor prognosis. Gestion o s.e.c.

12 C) Case 1: Spinoff Company by o (AngioChem AngioChem) AngioChem Now : It is pursuing the preclinical development of its lead molecule (Paclitaxel/AngioPep) against brain tumour anticipating a human Phase I clinical trial by the end of In vivo results = $$$... AngioChem has closed in 2005 a seed equity financing of 1 Million $ with the Business Development Bank of Canada and is actively looking for additional financing. Challenges & steps after a startup: Management recruitment, financing, feeding the pipeline. External CEO & CSO (Drs. Dugré & Gabathuler). Gestion o s.e.c.

13 D) Case 2: biotech transfer through licenses ; (enteric coating technology) Applications: This technology based on starch is compact at acid ph and swells at ph 7.2 and over. Suitable particularly for duodenal delivery of probiotics & pancreatic enzymes. Benefits: Direct Compression of Mixed Powders = No Other Coating Needed High Loading Capacity (80 %) Gastroresistance Stability not influenced by compression (tablet elasticity) The patent application (WO ) & the development were funded by o. Gestion o s.e.c.

14 D) Case 2: biotech transfer through licenses ; (enteric coating technology) GASTRIC PROTECTION (acid ph: 1.2) Number of CFU/10 mg L. rhamnosus 1.00E E E E E E E E E E E+00 Lactobacillus rhamnosus Lactobacillus rhamnosus + CMS Time (min) Gestion o s.e.c.

15 D) Case 2: biotech transfer through licenses ; (enteric coating technology) Why not a spinoff, even though this is a technology platform? More than 400 companies in the field of drug delivery Multiple polymers are used for enteric coating Benefits for the industry are related to steps saving Applicable preferably to a few niche markets Stats on biotech licenses* (US dollars): 3.9 % royalties (n= 24) Minimum annual royalty = $ (n=11) Upfront fee = $ (n=11) Many more types of payments possible (research fees, milestones) *Edwards et al., Value creation and sharing among universities, biotechnology and pharma; Nature Biotechnology, vol. 21, #6, p , June Gestion o s.e.c.

16 E) Concluding Remarks Commercialisation allows wide diffusion of the technologies Pasteur Keep promoting basic science that feeds the pipeline! Competition is the best stimulus! 2 examples: Pasteur versus Koch (studies on cholera) Antiarthritis drugs: Merck (Vioxx) vs. Pfizer (Celebrex); new paradigm in treatment Time to market notion critical for success Koch Gestion o s.e.c.

17 E) Concluding Remarks There is no category of science that can be named applied science. There is science and the applications of science, bound to each other like fruit to the tree that bears it. Louis Pasteur, 1871 Gestion o s.e.c.

18 E) Concluding Remarks For more information on the career in Life science commercialization, you may consult my interview to Microbiology Today, May 05; Society for General Microbiology, (http://www.socgenmicrobiol.org.uk/pubs/micro_today/pdf/ pdf ) Gestion o s.e.c.

19 HVALA DANKE DANK U MERCI GRÀCIES GRACIAS GRAZIE TAKK THANK YOU GO RAIBH MAITH AGAT MANY THANKS TO: LYSIANE LEGAULT (HEC ( MONTRÉAL) EMMANUELLE LÉON PROFESSOR ESCP EAP FRANCE MARIE LAURENCE LEMAIRE PROGRAM MANAGER ESCP EAP FRANCE PATRICK COHENDET PROFESSOR HEC MONTRÉAL FRANCE LAURENT SIMON PROFESSOR HEC MONTRÉAL France NATACHA MONGEAU (VALEO) AND THE ATTENDEES FROM ESCP EAP!!

PROMETIC LIFE SCIENCES INC.

PROMETIC LIFE SCIENCES INC. PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

Biotechnology in Canada - A Regional View. February 2004 Life Sciences Branch Industry Canada

Biotechnology in Canada - A Regional View. February 2004 Life Sciences Branch Industry Canada Biotechnology in Canada - A Regional View February 2004 Life Sciences Branch Industry Canada Objective and Contents Objective: This presentation compares key biotechnology statistics across Canadian regions

More information

Sosei acquires Jitsubo, a leading Japanese peptide technology company

Sosei acquires Jitsubo, a leading Japanese peptide technology company Sosei acquires Jitsubo, a leading Japanese peptide technology company Tokyo, Japan 11 December 2014: Sosei Group Corporation ( The Group ; TSE Mothers Index: 4565) is pleased to announce that at the meeting

More information

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Brilliance in photodynamic technology TM Photocure ASA Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Agreement with Salix

More information

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened

More information

Information required for the smooth functioning of the CREPUQ student exchange programs

Information required for the smooth functioning of the CREPUQ student exchange programs Information required for the smooth functioning of the CREPUQ student exchange programs 2012-2013 1. SEP WEB SITE http://echanges-etudiants.crepuq.qc.ca To register online for the CREPUQ student exchange

More information

A career on the science park

A career on the science park A career on the science park Onno van de Stolpe December 2014 Copyright 2014 Galapagos NV 1987 MOGEN Agricultural biotech pioneer Design of transgenic plants with improved traits Close link with Prof Schilperoort

More information

TRANSCRIPT OF EARNINGS CONFERENCE CALL MAY 16, 2013 AT 9.00 P.M. ET

TRANSCRIPT OF EARNINGS CONFERENCE CALL MAY 16, 2013 AT 9.00 P.M. ET TRANSCRIPT OF EARNINGS CONFERENCE CALL MAY 16, 2013 AT 9.00 P.M. ET Present: Mohd Aris Bernawi Chairman and CEO President & Secretary Dave Wong Chief Financial Officer Good evening ladies and gentlemen.

More information

Leading the shift in Business Technology Education

Leading the shift in Business Technology Education Leading the shift in Business Technology Education ITAC Talent Inspiring Tech Careers Inspiring Tech Careers Thank you for your interest in the ITAC Talent Business Technology Des carrières technologiques

More information

ico Therapeutics Inc. Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 (in Canadian dollars)

ico Therapeutics Inc. Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 (in Canadian dollars) Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 Balance Sheet (Unaudited) Assets Note September 30, 2012 December 31, 2011 Current assets Cash and cash equivalents 1,478,167

More information

Building innovative drug discovery alliances. Profitable. Growth Go

Building innovative drug discovery alliances. Profitable. Growth Go Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains

More information

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally External

More information

using the fully human ADLib system

using the fully human ADLib system Company Research and Analysis Report FISCO Ltd. http://www.fisco.co.jp 伪 伪 Focusing on improving technology to obtain antibodies using the fully human ADLib system (4583) (subsequently, the company ) is

More information

Bioscientists and Biotechnology: A Canadian Study

Bioscientists and Biotechnology: A Canadian Study Bioscientists and Biotechnology: A Canadian Study By Johanne Queenton and Jorge Niosi, Canada Research Chair in High Technology Management, UQAM, Montreal, Canada Introduction How to explain the growth

More information

Ten Billion Eggs for Mental Health

Ten Billion Eggs for Mental Health Ten Billion Eggs for Mental Health United Paragon Associates Inc April 2013 United Paragon Associates A private Canadian biotech company Discovered a novel potential treatment for MDD, Rellidep TM Completed

More information

Biotech Opportunities for Start-Up Firms in Japan and Asia

Biotech Opportunities for Start-Up Firms in Japan and Asia Biotech Opportunities for Start-Up Firms in Japan and Asia - Corporate VC s Perspective - Yoshitaka Yoneyama, Ph.D. President & CEO Astellas Venture Management LLC. April 25, 2006 About Astellas Pharma

More information

Click to edit Master title style. Investor Presentation. June 23, 2016. nuvopharmaceuticals.com TSX: NRI Nuvo Pharmaceuticals Inc.

Click to edit Master title style. Investor Presentation. June 23, 2016. nuvopharmaceuticals.com TSX: NRI Nuvo Pharmaceuticals Inc. Click to edit Master title style Investor Presentation June 23, 2016 nuvopharmaceuticals.com Nuvo Pharmaceuticals Inc. Click Safe Harbour to edit Master title style Certain information to be discussed

More information

DRAFT TABLE OF CONTENTS 1. Software Quality Assurance By Dr. Claude Y Laporte and Dr. Alain April

DRAFT TABLE OF CONTENTS 1. Software Quality Assurance By Dr. Claude Y Laporte and Dr. Alain April DRAFT TABLE OF CONTENTS 1 Software Quality Assurance By Dr. Claude Y Laporte and Dr. Alain April Foreword This book introduces the basic concepts of software quality assurance. The book illustrates how

More information

Meeting Priorities of Biotech & Small Pharma Companies

Meeting Priorities of Biotech & Small Pharma Companies Meeting Priorities of Biotech & Small Pharma Companies Dr. Andreas Orfanos, MBBCH,FFPM,MBA Thrasos Therapeutics Inc. Vice President Clinical Research & Development 28 Oct 2015 Montreal Technoparc Private,

More information

Objectives of Presentation. Licensing in Biotech: A Business Development View. Definition of Biotech. The Biotech Window

Objectives of Presentation. Licensing in Biotech: A Business Development View. Definition of Biotech. The Biotech Window Licensing in Biotech: A Business Development View Objectives of Presentation Identify the dynamic forces inside a biotech company that influence license negotiation process Bus. 771 Simon Fraser University

More information

Eudendron: an Innovative Biotech Start-up

Eudendron: an Innovative Biotech Start-up Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description

More information

A Texas Life Science Perspective. Thomas R. Kowalski President Texas Healthcare and Bioscience Institute

A Texas Life Science Perspective. Thomas R. Kowalski President Texas Healthcare and Bioscience Institute A Texas Life Science Perspective Thomas R. Kowalski President Texas Healthcare and Bioscience Institute 1 What is THBI? The Texas Healthcare and Bioscience Institute (THBI) is a non-profit, public policy

More information

Pharming Group NV Interim Report January - September 2015

Pharming Group NV Interim Report January - September 2015 Pharming Group NV Interim Report January - September Leiden, The Netherlands, 28 October, Biotech company Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) presents its (unaudited)

More information

Raising Capital for Life Sciences Companies US IPOs, Mezzanine Rounds, Strategic Partnerships and License Agreements

Raising Capital for Life Sciences Companies US IPOs, Mezzanine Rounds, Strategic Partnerships and License Agreements Raising Capital for Life Sciences Companies US IPOs, Mezzanine Rounds, Strategic Partnerships and License Agreements November 2015 Presented by: Stephen Thau 2 BIOTECH IPOS ARE HOT! The Biggest Biotech

More information

Revenue from contracts with customers The standard is final A comprehensive look at the new revenue model

Revenue from contracts with customers The standard is final A comprehensive look at the new revenue model Revenue from contracts with customers The standard is final A comprehensive look at the new revenue model No. 2014-01 (supplement) 11 June 2014 What s inside: Overview... 1 Scope... 2 Licences and rights

More information

Career Opportunities in the Life Sciences

Career Opportunities in the Life Sciences Career Opportunities in Biotechnology and Drug Career Opportunities in the Life Sciences Toby Beth Freedman, Ph.D. February 28 th, 2008 1 The Experiment A comprehensive, systematic assessment of careers

More information

Memorial University of Newfoundland 2,550 2,550 8,800 8,800. University of Prince Edward Island 5,360 5,360 11,600 11,600

Memorial University of Newfoundland 2,550 2,550 8,800 8,800. University of Prince Edward Island 5,360 5,360 11,600 11,600 TUITION FEES BY CANADIAN UNIVERSITY University tuition fees for full-time Canadian and international students in an arts and humanities program (unless otherwise indicated) at the undergraduate level at

More information

PCI Biotech Holding ASA - Second Quarter Report 2008

PCI Biotech Holding ASA - Second Quarter Report 2008 PCI Biotech Holding ASA - Second Quarter Report 2008 Highlights Demerger and Initial Public Offering at Oslo Axess in June Raised NOK 60 million Per Walday, PhD hired as new CEO Board has been strengthened

More information

The Board reviews risks to the Company s business plan at its scheduled meetings.

The Board reviews risks to the Company s business plan at its scheduled meetings. Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

INSIDE Secure. October 30, 2015. Third Quarter 2015 Revenue. Amedeo D Angelo, CEO Richard Vacher Detournière, GM & CFO

INSIDE Secure. October 30, 2015. Third Quarter 2015 Revenue. Amedeo D Angelo, CEO Richard Vacher Detournière, GM & CFO INSIDE Secure Third Quarter 2015 Revenue Amedeo D Angelo, CEO Richard Vacher Detournière, GM & CFO October 30, 2015 DISCLAIMER This communication does not constitute an offer to purchase or exchange or

More information

Valuations. The Effect of the Credit Crunch, US Healthcare Reform and the Shortage of New Innovative Products. Medius Associates.

Valuations. The Effect of the Credit Crunch, US Healthcare Reform and the Shortage of New Innovative Products. Medius Associates. Licensing Valuations Deal The Effect of the Credit Crunch, US Healthcare Reform and the Shortage of New Innovative Products Medius Associates Roger Davies This article was borne from personal experience

More information

Orphan Pharma: pathfinders for an increasingly specialised industry

Orphan Pharma: pathfinders for an increasingly specialised industry Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty

More information

Click to edit Master title style. Investor Presentation. September 12, 2016. nuvopharmaceuticals.com TSX: NRI Nuvo Pharmaceuticals Inc.

Click to edit Master title style. Investor Presentation. September 12, 2016. nuvopharmaceuticals.com TSX: NRI Nuvo Pharmaceuticals Inc. Click to edit Master title style Investor Presentation September 12, 2016 nuvopharmaceuticals.com Nuvo Pharmaceuticals Inc. Click Safe Harbour to edit Master title style Certain information to be discussed

More information

Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015

Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015 Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015 Product revenue guidance for 2015 of $170-$185 million reaffirmed Conference call with management to take place at 10:00 am ET on

More information

Recent Global Trends and Opportunities in Pharmaceutical Business. Doğan FIDAN, MD, PhD, MBA

Recent Global Trends and Opportunities in Pharmaceutical Business. Doğan FIDAN, MD, PhD, MBA Recent Global Trends and Opportunities in Pharmaceutical Business Doğan FIDAN, MD, PhD, MBA Conference Centre Swissotel Krasnye Holmy Moscow, 3 March 2015 Outline Review of the global trends that affect

More information

The Real Story Behind Big Pharma s R&D Spending in Canada

The Real Story Behind Big Pharma s R&D Spending in Canada The Real Story Behind Big Pharma s R&D Spending in Canada Canadian Generic Pharmaceutical Association 2008 Canadian Generic Pharmaceutical Association 4120 Yonge Street, Suite 409, Toronto ON M2P 2B8 Tel:

More information

Risk & Reward in de Venture Capital wereld

Risk & Reward in de Venture Capital wereld Risk & Reward in de Venture Capital wereld Risk & Reward seminar voor de biotech-, farma en life sciences industrie 24 maart 2011 Hermitage Amsterdam Dr. John de Koning Partner Venture Capital Introduction

More information

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

EMPLOYEE INVENTOR COMPENSATION PRACTICES SURVEY

EMPLOYEE INVENTOR COMPENSATION PRACTICES SURVEY EMPLOYEE INVENTOR COMPENSATION PRACTICES SURVEY Report of the IPO Asian Practice Committee February 2004 Intellectual Property Owners Association 1255 23 rd Street, NW, Suite 200 Washington, DC 20037 P:

More information

DIVERSIFIED LEADER IN HEALTHCARE STAFFING & OUTSOURCING

DIVERSIFIED LEADER IN HEALTHCARE STAFFING & OUTSOURCING DIVERSIFIED LEADER IN HEALTHCARE STAFFING & OUTSOURCING NURSE & ALLIED STAFFING PHYSICIAN STAFFING CLINICAL TRIALS SERVICES EDUCATION & RETAINED SEARCH February 2009 This presentation contains forward-looking

More information

BENCHMARKING OF BUSINESS INCUBATORS. in the Republic of Moldova. Aurelia Braguta

BENCHMARKING OF BUSINESS INCUBATORS. in the Republic of Moldova. Aurelia Braguta BENCHMARKING OF BUSINESS INCUBATORS in the Republic of Moldova by Aurelia Braguta BENCHMARKING OF BUSINESS INCUBATORS in the Republic of Moldova 1. Does a business incubator need to have a business plan

More information

Trends in Innovation in Middle Income Countries: The Case of Biotechnology

Trends in Innovation in Middle Income Countries: The Case of Biotechnology Trends in Innovation in Middle Income Countries: The Case of Biotechnology Joseph Damond, Senior Vice President, International Affairs, Biotechnology Industry Organization INNOVATION AND ACCESS TO MEDICAL

More information

Policy Based Pull Incentives for Creating Breakthrough CNS Drugs

Policy Based Pull Incentives for Creating Breakthrough CNS Drugs Policy Based Pull Incentives for Creating Breakthrough CNS Drugs Jan 20, 2015 Financial Incentives Workshop Neuroscience Forum, IOM Washington, DC Dennis W. Choi, MD, PhD SUNY Stony Brook Key Assumptions

More information

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, 11 March 2008 Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, France, March 11, 2008 Transgene (Euronext Paris: FR0005175080) announces

More information

Management Discussion and Analysis of the Financial Condition and Results of Operations

Management Discussion and Analysis of the Financial Condition and Results of Operations Management Discussion and Analysis of the Financial Condition and Results of Operations Fiscal 2014 First Quarter for the three months ended July 31, 2013 Table of Contents Overview 1 Forward looking Statements

More information

Canadian Life Sciences Industry Forecast 2007

Canadian Life Sciences Industry Forecast 2007 Canadian Life Sciences Industry Forecast 2007 Table of Contents Introduction 1 Key Findings 3 1. Financing continues to be the most critical success factor 4 2. Raising funds in the US is a challenge 5

More information

Commerzbank Sector Conference. Frankfurt August 30, 2011

Commerzbank Sector Conference. Frankfurt August 30, 2011 Commerzbank Sector Conference Frankfurt August 30, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

University of Minnesota Start-up Guide

University of Minnesota Start-up Guide University of Minnesota Start-up Guide Office for Technology Commercialization (OTC) - Venture Center A guide for faculty, staff, and entrepreneurs interested in starting a new business based on University

More information

January 3rd, 2012. Dear Subscriber,

January 3rd, 2012. Dear Subscriber, EnWave s mission is to establish REV as a new global dehydration standard: faster and cheaper than freeze drying, with better quality than air drying or spray drying." January 3rd, 2012 Dear Subscriber,

More information

EVT Execute & EVT Innovate Leading drug discovery

EVT Execute & EVT Innovate Leading drug discovery EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

Trends in IP strategy for young companies viewed from a larger company

Trends in IP strategy for young companies viewed from a larger company Trends in IP strategy for young companies viewed from a larger company Dr David Deperthes Vice President, BD&L, Debiopharm Int. CEO, Debiopharm Diagnostics Agenda General Information on Intellectual Property

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Selected performance measures January 2012

Selected performance measures January 2012 Selected performance measures January 2012 UVic excellence internationally recognized UVic ranked among the top 200 universities in the world Faculty success: research funding Over the past ten years,

More information

2014 Onxeo Review and 2015 Perspectives

2014 Onxeo Review and 2015 Perspectives 2014 Onxeo Review and 2015 Perspectives 2014 Consolidated Financial Results - Successful strategic merger and acquisition of Danish company Topotarget giving birth to Onxeo - Products major achievements:.

More information

Creative financing: Private equity in life sciences

Creative financing: Private equity in life sciences : Private equity in life sciences The Colonnade Hotel, Boston, MA October 28, 2008 Industry trends and implications 2 Setting the Stage Overall trends Aging population Emerging market opportunities - access

More information

Life Sciences Outlook Switzerland. 2012

Life Sciences Outlook Switzerland. 2012 Life Sciences Switzerland. 2012 Switzerland clusters driving scientific innovation Basal (BioValley) Switzerland s largest life sciences hub and the nexus of industry leaders France, Germany and Switzerland

More information

Company Profile // May 2012

Company Profile // May 2012 Company Profile // May 2012 1 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for

More information

Business development and strategic planning services. for life sciences and medtech ventures

Business development and strategic planning services. for life sciences and medtech ventures Business development and strategic planning services for life sciences and medtech ventures ttopstart - Business development and strategic planning services Design: Studio Edwin de Boer Business development

More information

Agenda Item 3. Discovery to Product Accelerator

Agenda Item 3. Discovery to Product Accelerator Agenda Item 3 Discovery to Product Accelerator BOARD OF REGENTS SUMMARY OF ITEM FOR ACTION INFORMATION OR DISCUSSION TOPIC: Discovery to Product Accelerator (information item) COMMITTEE: Economic Development

More information

Life Science - a sustainable platform for profitable growth

Life Science - a sustainable platform for profitable growth Life Science - a sustainable platform for profitable growth 2012 Life Science Information Day Bernd Reckmann Member of the Executive Board and Head of Chemicals Molsheim, France - December 5, 2012 Agenda

More information

18 avenue Antonine-Maillet miguel.rojas@umoncton.ca. +1-506 858-4093 (Fax)

18 avenue Antonine-Maillet miguel.rojas@umoncton.ca. +1-506 858-4093 (Fax) 18 avenue Antonine-Maillet miguel.rojas@umoncton.ca E1A 3E9 Moncton, NB +1-506 858-4219 (Office) Canada +1-506 858-4093 (Fax) Languages: English, French, Spanish EDUCATION Ph. D., Administration (Finance,

More information

Sales Force Effectiveness in Pharmaceuticals

Sales Force Effectiveness in Pharmaceuticals Sales Force Effectiveness in Pharmaceuticals Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency GBI Research Report

More information

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully

More information

Vectura Group plc. Annual Report and Accounts 2015

Vectura Group plc. Annual Report and Accounts 2015 RNS Number : 1783Q Vectura Group plc 15 June 2015 15 June 2015 Vectura Group plc Annual Report and Accounts 2015 In accordance with the Listing Rule 9.6.1, a copy of the following document has been submitted

More information

BioPharmaceutical Royalty Rates & Deal Terms Report. Licensing Executives Society (U.S.A. & Canada), Inc.

BioPharmaceutical Royalty Rates & Deal Terms Report. Licensing Executives Society (U.S.A. & Canada), Inc. BioPharmaceutical Royalty Rates & Deal Terms Report Licensing Executives Society (U.S.A. & Canada), Inc. June 2008 Table of Contents Introductory Letter 1 LES Survey Committee 2 Introduction 3 Report Highlights

More information

TITAN MEDICAL INC. Unaudited Condensed Interim Financial Statements Three and Six Months Ended June 30, 2013 and 2012

TITAN MEDICAL INC. Unaudited Condensed Interim Financial Statements Three and Six Months Ended June 30, 2013 and 2012 Unaudited Condensed Interim Financial Statements Three and and 2012 Unaudited Condensed Interim Balance Sheets As at June 30, 2013 and December 31, 2012 ASSETS CURRENT June 30, 2013 December 31, 2012 Cash

More information

improving nature s own defense mechanisms Company presentation

improving nature s own defense mechanisms Company presentation improving nature s own defense mechanisms Company presentation August 2013 Lytix Biopharma AS Norwegian non-listed company Founded 2003 Tromsø Aims to develop novel therapeutics for areas of high unmet

More information

Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop

Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop This presentation contains certain forward-looking statements. These forward-looking statements

More information

For personal use only

For personal use only APPENDIX 4D INTERIM FINANCIAL REPORT RESULTS FOR ANNOUNCEMENT TO THE MARKET Appendix 4D item 2.1 Revenue from ordinary activities. Appendix 4D item 2.2 Profit (loss) from ordinary activities after tax

More information

The Swedish Drug Development Pipeline June 2012. A survey conducted by:

The Swedish Drug Development Pipeline June 2012. A survey conducted by: The Swedish Drug Development Pipeline June 2012 A survey conducted by: Key findings More companies report clinical trials There has been a increase in number of companies contributing with information

More information

IP and Finance - Accounting and Valuation of IP Assets and IP-based Financing - Topic 13 -

IP and Finance - Accounting and Valuation of IP Assets and IP-based Financing - Topic 13 - IP and Finance - Accounting and Valuation of IP Assets and IP-based Financing - Topic 13 - McLean Sibanda Partner: Sibanda & Zantwijk Attorneys, South Africa Training of the Trainers Program on Effective

More information

The world leader in photodynamic technology

The world leader in photodynamic technology Brilliance in photodynamic technology TM The world leader in photodynamic technology Presentation of third quarter 2010 results 27 October 2010 Kjetil Hestdal, President & CEO Christian Fekete, CFO The

More information

White Paper January 2009. Top Ten Reports in Clinical Performance Management

White Paper January 2009. Top Ten Reports in Clinical Performance Management White Paper January 2009 Top Ten Reports in Clinical Performance Management 2 Contents 3 The solution Clinical Performance Management Clinical Trail Resource Planning Reports Report #1 Clinical Trial Project

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

Annual Report on Form 20-F

Annual Report on Form 20-F Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines

More information

Programa Cooperación Farma-Biotech Neurociencias NT-KO-003

Programa Cooperación Farma-Biotech Neurociencias NT-KO-003 Programa Cooperación Farma-Biotech Neurociencias NT-KO-003 A new oral treatment for Multiple Sclerosis based on a novel mechanism of action Barcelona, 15 de febrero 2011 Programa Cooperación Farma-Biotech

More information

EVT Execute & EVT Innovate World-class drug discovery

EVT Execute & EVT Innovate World-class drug discovery EVT Execute & EVT Innovate World-class drug discovery Evotec AG, First Quarter Report 2015, 12 May 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements,

More information

Spinnovator Public Private Partnership for Spin-offs

Spinnovator Public Private Partnership for Spin-offs A project of Ascenion and Vesalius Biocapital supported by the BMBF 5th International VPM Days Hannover Spinnovator Public Private Partnership for Spin-offs Christian Stein, September 1, 2011 Ascenion

More information

2014 Report: biotechnologies in the Italian pharmaceutical sector

2014 Report: biotechnologies in the Italian pharmaceutical sector 2014 Report: biotechnologies in the Italian pharmaceutical sector In collaboration with Assobiotec Executive summary Executive summary Executive summary Biotechnologies have always influenced all spheres

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity

More information

Poxel Raises 16 million in a Series A Financing to Accelerate Pipeline Development

Poxel Raises 16 million in a Series A Financing to Accelerate Pipeline Development Poxel Raises 16 million in a Series A Financing to Accelerate Pipeline Development Lyon, France, July 8, 2010 -, a diabetes drug development specialist, announces today that it has raised 16 million (USD

More information

Funding Canadian Biotechnology Companies

Funding Canadian Biotechnology Companies Funding Canadian Biotechnology Companies Borys Chabursky President & Founder A leading global biotech consultancy Toronto, Ontario, CANADA www.shi.ca 1 Objectives Canadian investment goals Government funding

More information

Flamel Technologies Provides Update on Corporate Progress

Flamel Technologies Provides Update on Corporate Progress Flamel Technologies Provides Update on Corporate Progress Clinical Programs Continue to Move Forward Outlines Full Year 2016 Revenue Guidance Lyon, France January 8, 2016 - Flamel Technologies (NASDAQ:

More information

REVIEW OF RESEARCH POLICY AND FUNDING ARRANGEMENTS FOR HIGHER EDUCATION

REVIEW OF RESEARCH POLICY AND FUNDING ARRANGEMENTS FOR HIGHER EDUCATION REVIEW OF RESEARCH POLICY AND FUNDING ARRANGEMENTS FOR HIGHER EDUCATION Response to the Issues Paper September 2015 Research Australia Page 1 About Research Australia Research Australia is an alliance

More information

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code

More information

Pharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells

Pharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells Pharmaceutical Report Royalty Purchasing Industry Thomas R. Wells Table of Contents Industry Overview 2 How Transactions Work 2 Advantages & Disadvantages for Inventors and Investors 4 Major Investors

More information

Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato

Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato Ennio Ongini Nicox Consiglio Nazionale delle Ricerche Quarta Giornata Informativa "Dalla ricerca al Trasferimento

More information

The Role of Research Institutions in the Formation of the Biotech Cluster in Massachusetts

The Role of Research Institutions in the Formation of the Biotech Cluster in Massachusetts The Role of Research Institutions in the Formation of the Biotech Cluster in Massachusetts Lita Nelsen Massachusetts Institute of Technology Cambridge, December 2005 The Massachusetts Biotech Cluster 2005

More information

Salary Survey 2014. Domestic, International Salary Survey and Country Cost Analysis

Salary Survey 2014. Domestic, International Salary Survey and Country Cost Analysis Salary Survey 2014 Domestic, International Salary Survey and Country Cost Analysis Disclaimer: This salary guides contained herewith have been constructed to represent average salaries across a range of

More information

UBS Global Life Sciences Conference 2011. New York September 19, 2011

UBS Global Life Sciences Conference 2011. New York September 19, 2011 UBS Global Life Sciences Conference 2011 New York September 19, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the

More information

ANTIBE THERAPEUTICS INC. CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2013

ANTIBE THERAPEUTICS INC. CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2013 ANTIBE THERAPEUTICS INC. CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2013 To the Shareholders of Antibe Therapeutics Inc. INDEPENDENT AUDITORS REPORT We have audited the accompanying consolidated financial

More information

1) SCOPE OF THE PROGRAM

1) SCOPE OF THE PROGRAM CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany

More information

A leading developer of placenta-based cell therapy products October 1, 2014

A leading developer of placenta-based cell therapy products October 1, 2014 Pluristem Therapeutics, Inc. Initiating Report A leading developer of placenta-based cell therapy products October 1, 2014 Key data Sector Rating Biotechnology BUY Target Price $21.00 Current Market Price

More information

The Commercialization of Technology Concepts into Medical Products

The Commercialization of Technology Concepts into Medical Products The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community

More information

Report on the Survey The Reality on Project Management Offices

Report on the Survey The Reality on Project Management Offices École des sciences de la gestion Université du Québec à Montréal Report on the Survey The Reality on Project Management Offices Brian Hobbs hobbs.brian@uqam.ca February 2006 Why this survey? To paint a

More information

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis Oncoxx Biotech Saverio Alberti Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis INTRODUCTION Oncoxx S.r.l. is a Cancer Biotech Company as partnership between Chieti University

More information